Heat shock protein 90-binding agents protect renal cells from oxidative stress and reduce kidney ischemia-reperfusion injury

被引:53
作者
Harrison, Ewen M. [1 ]
Sharpe, Eva [1 ]
Bellamy, Christopher O. [2 ]
McNally, Stephen J. [1 ]
Devey, Luke [1 ]
Garden, O. James [1 ]
Ross, James A. [1 ]
Wigmore, Stephen J. [1 ]
机构
[1] Univ Edinburgh, Tissue Injury & Repair Grp, Edinburgh EH16 4SB, Midlothian, Scotland
[2] Univ Edinburgh, Dept Pathol, Edinburgh EH16 4SB, Midlothian, Scotland
基金
英国医学研究理事会;
关键词
kidney transplantation; ischemia-reperfusion injury; oxidative stress; geldanamycin;
D O I
10.1152/ajprenal.00361.2007
中图分类号
Q4 [生理学];
学科分类号
071003 ;
摘要
Heat shock proteins (Hsps) are protective in models of transplantation, yet practical strategies to upregulate them remain elusive. The heat shock protein 90-binding agent (HBA) geldanamycin and its analogs (17-AAG and 17-DMAG) are known to upregulate Hsps and confer cellular protection but have not been investigated in a model relevant to transplantation. We examined the ability of HBAs to upregulate Hsp expression and confer protection in renal adenocarcinoma (ACHN) cells in vitro and in a mouse model of kidney ischemia-reperfusion (I/R) injury. Hsp70 gene expression was increased 30-40 times in ACHN cells treated with HBAs, and trimerization and DNA binding of heat shock transcription factor-1 (HSF1) were demonstrated. A three-and twofold increase in Hsp70 and Hsp27 protein expression, respectively, was found in ACHN cells treated with HBAs. HBAs protected ACHN cells from an H2O2-mediated oxidative stress, and HSF1 short interfering RNA was found to abrogate HBA-mediated Hsp induction and protection. In vivo, Hsp70 was upregulated in the kidneys, liver, lungs, and heart of HBA-treated mice. This was associated with a functional and morphological renal protection from I/R injury. Therefore, HBAs mediate upregulation of protective Hsps in mouse kidneys which are associated with reduced I/R injury and may be useful in reducing transplant-associated kidney injury.
引用
收藏
页码:F397 / F405
页数:9
相关论文
共 59 条
[1]   HSP90 interacts with and regulates the activity of heat shock factor 1 in Xenopus oocytes [J].
Ali, A ;
Bharadwaj, S ;
O'Carroll, R ;
Ovsenek, N .
MOLECULAR AND CELLULAR BIOLOGY, 1998, 18 (09) :4949-4960
[2]   Induction of multiple heat shock proteins and neuroprotection in a primary culture model of familial amyotrophic lateral sclerosis [J].
Batulan, Zarah ;
Taylor, David M. ;
Aarons, Rebecca J. ;
Minotti, Sandra ;
Doroudchi, Mohammad. M. ;
Nalbantoglu, Josephine ;
Durham, Heather D. .
NEUROBIOLOGY OF DISEASE, 2006, 24 (02) :213-225
[3]   Ischemic acute renal failure: An inflammatory disease? [J].
Bonventre, JV ;
Zuk, A .
KIDNEY INTERNATIONAL, 2004, 66 (02) :480-485
[4]   Heat shock factor 1 and heat shock proteins: Critical partners in protection against acute cell injury [J].
Christians, ES ;
Yan, LJ ;
Benjamin, IJ .
CRITICAL CARE MEDICINE, 2002, 30 (01) :S43-S50
[5]   Gene expression profiling of human colon cancer cells following inhibition of signal transduction by 17-allylamino-17-demethoxygeldanamycin, an inhibitor of hsp90 molecular chaperone [J].
Clarke, PA ;
Hostein, I ;
Banerji, U ;
Di Stefano, F ;
Maloney, A ;
Walton, M ;
Judson, I ;
Workman, P .
ONCOGENE, 2000, 19 (36) :4125-4133
[6]   Induction of heat shock proteins by tyrosine kinase inhibitors in rat cardiomyocytes and myogenic cells confers protection against simulated ischemia [J].
Conde, AG ;
Lan, SS ;
Dillmann, WH ;
Mestril, R .
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 1997, 29 (07) :1927-1938
[7]   The heat-shock protein 90 inhibitor 17-allylamino-17-demethoxygeldanamycin suppresses glial inflammatory responses and ameliorates experimental autoimmune encephalomyelitis [J].
Dello Russo, Cinzia ;
Polak, Paul E. ;
Mercado, Pilar R. ;
Spagnolo, Alessandra ;
Sharp, Anthony ;
Murphy, Patricia ;
Kamal, Adeela ;
Burrows, Francis J. ;
Fritz, Lawrence C. ;
Feinstein, Douglas L. .
JOURNAL OF NEUROCHEMISTRY, 2006, 99 (05) :1351-1362
[8]   Cytoprotection against thermal injury: Evaluation of herbimycin A by cell viability and cDNA arrays [J].
Dihn H.K. ;
Stavchansky S. ;
Schuschereba S.T. ;
Stuck B.E. ;
Bowman P.D. .
The Pharmacogenomics Journal, 2002, 2 (5) :318-326
[9]   Pharmacokinetics, tissue distribution, and metabolism of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin (NSC 707545) in CD2F1 mice and Fischer 344 rats [J].
Egorin, MJ ;
Lagattuta, TF ;
Hamburger, DR ;
Covey, JM ;
White, KD ;
Musser, SM ;
Eiseman, JL .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2002, 49 (01) :7-19
[10]   Pharmacokinetics and pharmacodynamics of 17-demethoxy 17-[[(2-dimethylamino)ethyl]amino]geldanamycin (17DMAG, NSC 707545) in C.B-17 SCID mice bearing MDA-MB-231 human breast cancer xenografts [J].
Eiseman, JL ;
Lan, J ;
Lagattuta, TF ;
Hamburger, DR ;
Joseph, E ;
Covey, JM ;
Egorin, MJ .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2005, 55 (01) :21-32